Vulvovaginal AtrophyPhase 3REJOICENCT02253173
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
A Phase 3 study testing Estradiol in people with Vulvovaginal Atrophy and Menopause, run by TherapeuticsMD at 105 sites in 2 countries.
Trial summary
This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women. Read more about this study
- Who is it for?
- Ages 40 to 75 years, women only
- Conditions the study is for
- Vulvovaginal Atrophy, Menopause, Dyspareunia
- What is being tested?
- Estradiol
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 764 participants
- Where
- 105 sitesin 2 countries
- Study dates
- Sep 2014to Oct 2015
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 75 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Postmenopausal female subjects between the ages of 40 and 75 years (at the time of randomization) with at least:
- 12 months of spontaneous amenorrhea (women <55 years of age with a history of hysterectomy without bilateral oophorectomy prior to natural menopause must have follicle stimulating hormone (FSH) levels > 40 mIU/mL), OR
- 6 months of spontaneous amenorrhea with follicle stimulating hormone (FSH) levels > 40mlU/mL OR
- At least 6 weeks postsurgical bilateral oophorectomy.
- ≤5% superficial cells on vaginal cytological smear
- Vaginal pH > 5.0
Show all 14Show fewer
- Moderate to severe symptom of vaginal pain associated with sexual activity considered the most bothersome vaginal symptom by the subject at screening visit 1A.
- Moderate to severe symptom of vaginal pain associated with sexual activity at screening visit 1B.
- Onset of moderate to severe dyspareunia in the postmenopausal years.
- Subjects should be sexually active (i.e. have sexual activity with vaginal penetration within approximately 1 month of screening visit 1A).
- Subjects should anticipate having sexual activity (with vaginal penetration) during the conduct of the trial.
- For subjects with an intact uterus: Subjects must have an acceptable result from an evaluable screening endometrial biopsy.
- Subjects who have a Body Mass Index (BMI) less than or equal to 38 kg/m2. BMI values should be rounded to the nearest integer (ex. 32.4 rounds down to 32, while 26.5 rounds up to 27).
- In the opinion of the investigator, the subject will comply with the protocol and has a high probability of completing the study.
Who cannot join
- Use of the following:
- Oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 8 weeks before screening visit 1A (can enter washout);
- Use of transdermal hormone products within 4 weeks before screening visit 1A (can enter washout);
- Use of vaginal hormone products (rings, creams, gels) within 4 weeks before screening visit1A (can enter washout);
- Use of intrauterine progestins within 8 weeks before screening visit 1A (can enter washout);
- Use of progestin implants/injectables or estrogen pellets/injectables within 6 months before screening visit 1A (cannot enter washout);
Show all 42Show fewer
- Use of vaginal lubricants or moisturizers within 7 days before the screening visit 1B vaginal pH assessment.
- A history or active presence of clinically important medical disease that might confound the study or be detrimental to the subject, examples include:
- Hypersensitivity to estrogens;
- Endometrial hyperplasia;
- Undiagnosed vaginal bleeding;
- Have a history of a chronic liver or kidney dysfunction/disorder (e.g., Hepatitis C or chronic renal failure);
- Thrombophlebitis, thrombosis or thromboembolic disorders;
- Cerebrovascular accident, stroke, or transient ischemic attack;
- Myocardial infarction or ischemic heart disease;
- Malignancy or treatment for malignancy, within the previous 5 years, with the exception of basal cell carcinoma of the skin or squamous cell carcinoma of the skin. A history of estrogen dependent neoplasia, breast cancer, melanoma or any gynecologic cancer, at any time, excludes the subject;
- Endocrine disease (except for controlled hypothyroidism or controlled non-insulin dependent diabetes mellitus).
- Recent history of known alcohol or drug abuse.
- History of sexual abuse or spousal abuse that, in the opinion of the PI, may interfere with the subject's assessment of vaginal pain with sexual activity.
- Current history of Heavy smoking (more than 15 cigarettes per day) or use of e-cigarettes.
- Use of an intrauterine device within 12 weeks before screening visit 1A.
- Use of an investigational drug within 60 days before screening visit 1A.
- Any clinically important abnormalities on screening physical exam, assessments, ECG, or laboratory tests, such as:
- Unresolved cervical cytologic smear report of atypical glandular cells of undetermined significance (AGUS) or atypical squamous cells of undetermined significance (ASCUS).
- Cervical cytologic smear report of low-grade squamous intraepithelial lesion (SIL) or greater, CIN1 or greater, or any reported dysplasia; Subjects with ASCUS are eligible only if high risk human papilloma virus (HPV) result is negative.
- Unresolved findings suspicious for malignancy on the breast exam; incomplete mammogram result (BI-RADS 0) or unresolved findings suggestive of malignant changes or findings requiring short interval follow-up on the prestudy mammogram (subjects must have mammography result of BI-RADS 1 or 2 to enroll.) Mammogram may be performed within 9 months prior to Visit 2 (randomization) with documentation available. (The site must obtain a copy of the official report for the subject's study file, and it must be verified that the mammogram itself is available if needed for additional assessment);
- In subjects with intact uterus: have a screening endometrial biopsy sample that is found by both primary pathologists to have endometrial tissue insufficient for diagnosis, no endometrium identified, or no tissue identified. (With the approval of the Medical Monitor, the screening endometrial biopsy may be repeated once);
- In subjects with intact uterus: an endometrial biopsy report by one central pathologist at screening with one of the following:
- Endometrial hyperplasia endometrial cancer, proliferative endometrium, weakly proliferative endometrium, disordered proliferative pattern; OR
- Endometrial polyps with hyperplasia, glandular atypia of any degree (e.g., atypical nuclei) or cancer;
- Vulvar or vaginal inflammatory condition such as a contact or allergic dermatitis, lichen sclerosis or other pathological findings;
- Presence of suspicious vulvar or vaginal lesions for dysplasia, malignancy or other pathology other than atrophy;
- Painful genital warts or localized areas of ulceration;
- A history of active, chronic pelvic pain;
- Interstitial cystitis;
- Serum alanine aminotransferase (ALT) or serum aspartate aminotransferase (AST) greater than 1.5 times the upper limit of normal for the laboratory used;
- Fasting total cholesterol greater than 300 mg/dL (7.77 mmol/L) or triglycerides greater than 300 mg/dL (3.39 mmol/L);
- Fasting blood glucose greater than 125 mg/dL (6.94 mmol/L) with a hemoglobin A1C of greater than or equal to 6.5%;
- Uncontrolled hypertension; subjects with elevated sitting blood pressure, greater than 140 mm Hg systolic or greater than 90 mm Hg diastolic and may not be using more than 2 antihypertensive medications for the treatment of hypertension;
- Clinically significant abnormal 12-lead ECG (such as myocardial infarction or other findings suggestive of ischemia)
- Be known to be pregnant or have a positive urine pregnancy test. (Note: A pregnancy test is not required for subjects who have had bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or are 55 years old or greater and have experienced cessation of menses for at least 1 year.
- Current use of marijuana.
Trial locations and contacts
105 sites in 2 countries.
105 sites in 2 countries
United States100 sites
Radiant Research
Akron, Ohio, 44311
Bosque Women's Care
Albuquerque, New Mexico, 87109
Southwest Clinical Research
Albuquerque, New Mexico, 87109
ClinSite, LLC
Ann Arbor, Michigan, 48106
Women's Health Associates
Atlanta, Georgia, 30342
Masters of Clinical Research, Inc.
Augusta, Georgia, 30909
South Florida Medical Research
Aventura, Florida, 33180
American Health Network of Indiana, LLC
Avon, Indiana, 46123
Sutter East Bay Medical Foundation
Berkeley, California, 94705
Montana Health
Billings, Montana, 59102
Fellows Research Alliance, Inc.
Bluffton, South Carolina, 29910
Advanced Clinical Research
Boise, Idaho, 83642
Chattanooga Medical Research
Chattanooga, Tennessee, 37404
Radiant Research
Chicago, Illinois, 60654
University of Cincinnati Physicians Company
Cincinnati, Ohio, 45267-0457
Rapid Medical Research
Cleveland, Ohio, 44122
Lynn Institute of the Rockies
Colorado Springs, Colorado, 80909
Vista Clinical Research
Columbia, South Carolina, 29201
Columbus Center for Women's Health Research
Columbus, Ohio, 43213
Advanced Research Associates
Corpus Christi, Texas, 78414
Nature Coast Clinical Research
Crystal River, Florida, 34429
Research Across America
Dallas, Texas, 75234
UT Southwestern Medical Center
Dallas, Texas, 75390-9032
Soapstone Center for Clinical Research
Decatur, Georgia, 30034
Avail Clinical Research
DeLand, Florida, 32720
Downtown Women's Health Care
Denver, Colorado, 80209
Horizons Clinical Research Center
Denver, Colorado, 80220
Women's Wellness Clinic
Durham, North Carolina, 27713
HWC Women's Research Center
Englewood, Ohio, 45322
Horizon Research Group of Opelousas
Eunice, Louisiana, 70535
Lillestol Research
Fargo, North Dakota, 58103
Clinical Physiology Associates
Fort Myers, Florida, 33916
Capital Women's Care
Frederick, Maryland, 21702
UF Health Physicians Women's & REI Springhill
Gainesville, Florida, 32606
Pinewest OB-GYN, Inc.
High Point, North Carolina, 27262
Advances in Health
Houston, Texas, 77030
Hwca, Pllc
Houston, Texas, 77054
TMC Life Research
Houston, Texas, 77054
Medical Affiliated Research Center
Huntsville, Alabama, 35801
Women's Healthcare Associates P.A.
Idaho Falls, Idaho, 83404
UF College of Medicine-Jacksonville, Dept. of Obstetrics and Gynecology
Jacksonville, Florida, 32207
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216
The Clinical Trial Center
Jenkintown, Pennsylvania, 19046
Beyer Research
Kalamazoo, Michigan, 49009
Lafayette Clinical Research Group
Lafayette, Indiana, 47905
Red Rocks OB/Gyn
Lakewood, Colorado, 80228
Office of Edmond E. Pack, MD
Las Vegas, Nevada, 89113
Office of R. Garn Mabey, MD
Las Vegas, Nevada, 89128
Lawrence OB-GYN Clinical Research, LLC
Lawrenceville, New Jersey, 08648
Central Kentucky Research Associates, Inc.
Lexington, Kentucky, 40509
Women's Clinic of Lincoln
Lincoln, Nebraska, 68510
Torrance Clinical Research Institute Inc
Lomita, California, 90717
Bluegrass Clinical Research, Inc.
Louisville, Kentucky, 40291
Maryland Center for Sexual Health
Lutherville, Maryland, 21093
South Florida Wellness & Clinical Research Institute
Margate, Florida, 33063
Landerbrook Health Center
Mayfield Heights, Ohio, 44124
Sunstone Medical Research
Medford, Oregon, 97504
Cactus Clinical Research
Mesa, Arizona, 85209
New Age Medical Research Corporation
Miami, Florida, 33186
Clinical Research Consulting
Milford, Connecticut, 06460
Montogomery Women's Health
Montgomery, Alabama, 36117
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, 29464
Rutgers-Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901
Coastal Connecticut Research, LLC
New London, Connecticut, 06320
Suncoast Clinical Research, Inc.
New Port Richey, Florida, 34652
Columbia University Medical Center
New York, New York, 10032
National Clinical Research-Norfolk
Norfolk, Virginia, 23502
Clinical Research Center, EVMS
Norfolk, Virginia, 23507
Healthcare Clinical Data
North Miami, Florida, 33161
Ideal Clinical Research
North Miami Beach, Florida, 33162
Futura Research
Norwalk, California, 90650
Clinical Research of Philadelphia
Philadelphia, Pennsylvania, 19114
Arizona Wellness Center for Women
Phoenix, Arizona, 85032
Radiant Research
Pinellas Park, Florida, 33781
Clinical Trials Research Services
Pittsburgh, Pennsylvania, 15206
Women's Health Research Center
Plainsboro, New Jersey, 08536
All Women's Healthcare of West Broward
Plantation, Florida, 33324
Suffolk OB/GYN
Port Jefferson, New York, 08536
Wake Research Associates
Raleigh, North Carolina, 27612
Virginia Women's Center, Inc.
Richmond, Virginia, 23233
National Clinical Research-Richmond, Inc
Richmond, Virginia, 23294
Northern California Research
Sacramento, California, 95821
Saginaw Valley Medical Research Group, L.L.C.
Saginaw, Michigan, 48604
Stone Oak, LLC dba Discovery Clinical Trials
San Antonio, Texas, 78258
Medical Center for Clinical Research
San Diego, California, 92108
San Diego Sexual Medicine
San Diego, California, 92120
Women's Health Care Research Corp.
San Diego, California, 92123
WR-Mount Vernon Clinical Research
Sandy Springs, Georgia, 30328
Physician Care Clinical Research
Sarasota, Florida, 34239
Fellows Research Alliance, Inc.
Savannah, Georgia, 31046
Radiant Research
Scottsdale, Arizona, 85251
Seattle Women's Health, Research, and Gynecology
Seattle, Washington, 98105
North Spokane Women's Health
Spokane, Washington, 99207
Visions Clinical Research - Tucson
Tucson, Arizona, 85712
Tidewater Clinical Research
Virginia Beach, Virginia, 23456
James A. Simon, Women's Health & Research Consultants
Washington D.C., District of Columbia, 20036
Comprehensive Clinical Trials
West Palm Beach, Florida, 33409
Cypress Medical Research Center
Wichita, Kansas, 67226
Hawthorne Research
Winston-Salem, North Carolina, 27103
Lyndhurst Clinical Research
Winston-Salem, North Carolina, 27103
Canada5 sites
Diex Research Montreal Inc.
Montreal, Quebec, H4N 3C5
Center for Research Saint-Louis
Québec, Quebec, G1W4R4
Clinique RSF Inc.
Québec, G1S 2L6
Manna Research Inc
Saint Romuald, Quebec, G6W 5M6
Diex Research Sherbrooke Inc.
Sherbrooke, Quebec, J1H 1Z1
About this study
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy
This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.
- Conditions
- Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
- Being tested
- Estradiol, Placebo
- Keywords
- VVA, Painful Sex, Postmenopausal
- Medical subject headings
- Dyspareunia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EstradiolDrug
PlaceboDrug
| Study group | Role | What they receive |
|---|---|---|
| Estradiol 4mcg Vaginal Softgel Capsule | Experimental | Estradiol 4mcg Vaginal Softgel Capsule Receives: Drug: Estradiol |
| Estradiol 10mcg Vaginal Softgel Capsule | Experimental | Estradiol 10mcg Vaginal Softgel Capsule Receives: Drug: Estradiol |
| Estradiol 25mcg Vaginal Softgel Capsule | Experimental | Estradiol 25mcg Vaginal Softgel Capsule Receives: Drug: Estradiol |
| Placebo Vaginal Softgel Capsule | Placebo comparator | Placebo Vaginal Softgel Capsule Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Co-Primary Efficacy Endpoint - Vaginal Superficial Cells
- Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
Measured: Baseline and 12 Weeks
Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells
- Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
Measured: Baseline and 12 Weeks
Co-Primary Efficacy Endpoint - Vaginal pH
- Change from Baseline to Week 12 in vaginal pH as compared to placebo
Measured: Baseline and 12 Weeks
Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia)
- Change from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 12
Measured: Baseline and Week 12
Secondary outcomes (43)
Secondary Efficacy Endpoints - Vaginal Superficial Cells
- Change from Baseline to Week 2 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
Measured: Baseline and Week 2
Secondary Efficacy Endpoints- Vaginal Superficial Cells
Change from Baseline to Week 6 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
Measured: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Superficial Cells
Change from Baseline to Week 8 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
Measured: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
Change from Baseline to Week 2 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
Measured: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
Change from Baseline to Week 6 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
Measured: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
Change from Baseline to Week 8 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
Measured: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal pH
Change from Baseline to Week 2 in vaginal pH as compared to placebo
Measured: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal pH
Change from Baseline to Week 6 in vaginal pH as compared to placebo
Measured: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal pH
Change from Baseline to Week 8 in vaginal pH as compared to placebo
Measured: Baseline and Week 8
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
Change from Baseline to Week 2 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 2
Measured: Baseline and Week 2
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
Change from Baseline to Week 6 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 6
Measured: Baseline and Week 6
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
Change from Baseline to Week 8 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 8
Measured: Baseline and Week 8
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Change from Baseline to Week 2 on the severity of vaginal dryness associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 2
Measured: Baseline and Week 2
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Change from Baseline to Week 6 on the severity of vaginal dryness associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 6
Measured: Baseline and Week 6
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Change from Baseline to Week 8 on the severity of vaginal dryness associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 8
Measured: Baseline and Week 8
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Change from Baseline to Week 12 on the severity of vaginal dryness associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 12
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Change from Baseline to Week 2 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 2
Measured: Baseline and Week 2
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Change from Baseline to Week 6 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 6
Measured: Baseline and Week 6
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Change from Baseline to Week 8 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 8
Measured: Baseline and Week 8
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Change from Baseline to Week 12 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo
VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe.
Subjects assessed severity at Baseline and Week 12
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Change from Baseline to Week 2 in Vaginal Color as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 2
Measured: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Change from Baseline to Week 6 in Vaginal Color as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 6
Measured: Baseline to Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Change from Baseline to Week 8 in Vaginal Color as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 8
Measured: Baseline to Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Change from Baseline to Week 12 in Vaginal Color as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 12
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Change from Baseline to Week 2 in Vaginal Epithelial Integrity as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3
Severity was assessed by the Investigator at Baseline and Week 2
Measured: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Change from Baseline to Week 6 in Vaginal Epithelial Integrity as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3
Severity was assessed by the Investigator at Baseline and Week 6
Measured: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Change from Baseline to Week 8 in Vaginal Epithelial Integrity as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3
Severity was assessed by the Investigator at Baseline and Week 8
Measured: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Change from Baseline to Week 12 in Vaginal Epithelial Integrity as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3
Severity was assessed by the Investigator at Baseline and Week 12
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Change from Baseline to Week 2 in Vaginal Epithelial Surface Thickness as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3
Severity was assessed by the Investigator at Baseline and Week 2
Measured: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Change from Baseline to Week 6 in Vaginal Epithelial Surface Thickness as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3
Severity was assessed by the Investigator at Baseline and Week 6
Measured: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Change from Baseline to Week 8 in Vaginal Epithelial Surface Thickness as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3
Severity was assessed by the Investigator at Baseline and Week 8
Measured: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Change from Baseline to Week 12 in Vaginal Epithelial Surface Thickness as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe [smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)] = 3
Severity was assessed by the Investigator at Baseline and Week 12
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Change from Baseline to Week 2 in Vaginal Secretions as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain) = 3
Severity was assessed by the Investigator at Baseline and Week 2
Measured: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Change from Baseline to Week 6 in Vaginal Secretions as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain] = 3
Severity was assessed by the Investigator at Baseline and Week 6
Measured: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Change from Baseline to Week 8 in Vaginal Secretions as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain] = 3
Severity was assessed by the Investigator at Baseline and Week 8
Measured: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Change from Baseline to Week 12 in Vaginal Secretions as compared to placebo
Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain] = 3
Severity was assessed by the Investigator at Baseline and Week 12
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score
Change from Baseline to Week 12 in FSFI Total Score as compared to placebo
The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal
Change from Baseline to Week 12 in FSFI Domain Score (Arousal) as compared to placebo
The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire
Change from Baseline to Week 12 in FSFI Domain Score (Desire) as compared to placebo
The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication
Change from Baseline to Week 12 in FSFI Domain Score (Lubrication) as compared to placebo
The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Orgasm
Change from Baseline to Week 12 in FSFI Domain Score (Orgasm) as compared to placebo
The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain
Change from Baseline to Week 12 in FSFI Domain Score (Pain) as compared to placebo
The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Measured: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction
Change from Baseline to Week 12 in FSFI Domain Score (Satisfaction) as compared to placebo
The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Measured: Baseline and Week 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Oct 2014 (estimated)
- Study startSep 2014
- Primary completionOct 2015
- Study completionOct 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Vulvovaginal AtrophyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 764 participants (actual)
Sponsor and investigators
- Lead sponsor
- TherapeuticsMD
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02253173
- Sponsor's protocol ID
- TXV14-01
- Acronym
- REJOICE
- Status last verified
- Apr 2017
- First submitted
- 26 Sep 2014
- Last updated
- 25 May 2017
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Lara LA, Cartagena-Ramos D, Figueiredo JB, Rosa-E-Silva ACJ, Ferriani RA, Martins WP, Fuentealba-Torres M. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2023 Aug 24;8(8):CD009672. doi: 10.1002/14651858.CD009672.pub3.
PubMed 37619252Mirkin S, Simon JA, Liu JH, Archer DF, Castro PD, Graham S, Bernick B, Komm B. Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert. Menopause. 2021 May 28;28(9):998-1003. doi: 10.1097/GME.0000000000001801.
PubMed 34054104Constantine G, Millheiser LS, Kaunitz AM, Parish SJ, Graham S, Bernick B, Mirkin S. Early onset of action with a 17beta-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia. Menopause. 2019 Nov;26(11):1259-1264. doi: 10.1097/GME.0000000000001394.
PubMed 31688572Constantine GD, Simon JA, Pickar JH, Archer DF, Bernick B, Graham S, Mirkin S. Estradiol vaginal inserts (4 microg and 10 microg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. Curr Med Res Opin. 2018 Dec;34(12):2131-2136. doi: 10.1080/03007995.2018.1527578. Epub 2018 Sep 28.
PubMed 30238814Constantine GD, Bouchard C, Pickar JH, Archer DF, Graham S, Bernick B, Mirkin S. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women. J Womens Health (Larchmt). 2017 Jun;26(6):616-623. doi: 10.1089/jwh.2016.6187. Epub 2017 Mar 29.
PubMed 28355090
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy
- ClinicalTrials.gov ID
- NCT02253173
- Acronym / sponsor ID
- REJOICE / TXV14-01
- Conditions
- Vulvovaginal Atrophy, Menopause, Dyspareunia, Painful Intercourse
- Keywords
- VVA, Painful Sex, Postmenopausal
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 764 participants (actual)
- Lead sponsor
- TherapeuticsMDIndustry (pharma, biotech, devices)
- Study start
- Sep 2014
- Primary completion
- Oct 2015 (actual)
- Study completion
- Oct 2015 (actual)
- First posted
- 1 Oct 2014 (estimated)
- Results
- Posted 25 May 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Estradiol 4mcg Vaginal Softgel Capsule | Experimental | Drug: EstradiolEstradiol 4mcg Vaginal Softgel Capsule |
| Estradiol 10mcg Vaginal Softgel Capsule | Experimental | Drug: EstradiolEstradiol 10mcg Vaginal Softgel Capsule |
| Estradiol 25mcg Vaginal Softgel Capsule | Experimental | Drug: EstradiolEstradiol 25mcg Vaginal Softgel Capsule |
| Placebo Vaginal Softgel Capsule | Placebo comparator | Drug: PlaceboPlacebo Vaginal Softgel Capsule |
Who may qualify
- Ages
- 40 to 75 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Postmenopausal female subjects between the ages of 40 and 75 years (at the time of randomization) with at least:
- ≤5% superficial cells on vaginal cytological smear
- Vaginal pH > 5.0
- Moderate to severe symptom of vaginal pain associated with sexual activity considered the most bothersome vaginal symptom by the subject at screening visit 1A.
- Moderate to severe symptom of vaginal pain associated with sexual activity at screening visit 1B.
Key exclusion criteria (42 listed)
- Use of the following:
- A history or active presence of clinically important medical disease that might confound the study or be detrimental to the subject, examples include:
- Recent history of known alcohol or drug abuse.
- History of sexual abuse or spousal abuse that, in the opinion of the PI, may interfere with the subject's assessment of vaginal pain with sexual activity.
- Current history of Heavy smoking (more than 15 cigarettes per day) or use of e-cigarettes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Estradiol | Drug | Estradiol 10mcg Vaginal Softgel Capsule, Estradiol 25mcg Vaginal Softgel Capsule, Estradiol 4mcg Vaginal Softgel Capsule |
| Placebo | Drug | Placebo Vaginal Softgel Capsule |
Primary outcome
Co-Primary Efficacy Endpoint - Vaginal Superficial Cells
Time frame: Baseline and 12 Weeks
• Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells
Time frame: Baseline and 12 Weeks
• Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
Co-Primary Efficacy Endpoint - Vaginal pH
Time frame: Baseline and 12 Weeks
• Change from Baseline to Week 12 in vaginal pH as compared to placebo
Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia)
Time frame: Baseline and Week 12
• Change from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12
43 secondary outcomes
Secondary Efficacy Endpoints - Vaginal Superficial Cells
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints- Vaginal Superficial Cells
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Superficial Cells
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal pH
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal pH
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal pH
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Time frame: Baseline to Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Time frame: Baseline to Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication
Time frame: Baseline and Week 12
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2017.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37619252Lara LA, Cartagena-Ramos D, Figueiredo JB, Rosa-E-Silva ACJ, Ferriani RA, Martins WP, Fuentealba-Torres M. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2023 Aug 24;8(8):CD009672. doi: 10.1002/14651858.CD009672.pub3.
- Derived from this study: PubMed 34054104Mirkin S, Simon JA, Liu JH, Archer DF, Castro PD, Graham S, Bernick B, Komm B. Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert. Menopause. 2021 May 28;28(9):998-1003. doi: 10.1097/GME.0000000000001801.
- Derived from this study: PubMed 31688572Constantine G, Millheiser LS, Kaunitz AM, Parish SJ, Graham S, Bernick B, Mirkin S. Early onset of action with a 17beta-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia. Menopause. 2019 Nov;26(11):1259-1264. doi: 10.1097/GME.0000000000001394.
- Derived from this study: PubMed 30238814Constantine GD, Simon JA, Pickar JH, Archer DF, Bernick B, Graham S, Mirkin S. Estradiol vaginal inserts (4 microg and 10 microg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. Curr Med Res Opin. 2018 Dec;34(12):2131-2136. doi: 10.1080/03007995.2018.1527578. Epub 2018 Sep 28.
- Derived from this study: PubMed 28355090Constantine GD, Bouchard C, Pickar JH, Archer DF, Graham S, Bernick B, Mirkin S. Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women. J Womens Health (Larchmt). 2017 Jun;26(6):616-623. doi: 10.1089/jwh.2016.6187. Epub 2017 Mar 29.
Related trials for Vulvovaginal Atrophy
RecruitingPhase 2
Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
Vulvo Vaginal Atrophy (VVA)
Recruiting
F-GYN for Vaginal Dryness and Vulvovaginal Atrophy
Atrophic Vaginitis, Atrophic Vulvovaginitis
Recruiting
A Laser and Topical Treatment Combination in the Vulvo-vaginal Atrophy Management in Breast Cancer Patients.
Female Urogenital Diseases, Breast Cancer Female
Not yet recruitingObservational study
Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
RecruitingObservational study
Determining the Extent of the Genitourinary Syndrome of Menopause Burden in Breast Cancer Survivors
Genitourinary Syndrome of Menopause (GSM), Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
105 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Estradiol in people with Vulvovaginal Atrophy and Menopause, run by TherapeuticsMD at 105 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 42 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 105 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 25 May 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Co-Primary Efficacy Endpoint - Vaginal Superficial Cells (time frame: Baseline and 12 Weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02253173, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2017.